Page 78 - Read Online

Page 22 of 29 Aguiar. Rare Dis Orphan Drugs J 2024;3:13 https://dx.doi.org/10.20517/rdodj.2023.56

2018;19:3726. DOI PubMed PMC
46. Aguiar P, Azevedo O, Marino J, Soares JLD, Hughes D. Plasma lyso-Gb3 in Fabry disease: helpful distinguishing phenotypes, but
not as predictor of organ involvement. Mol Genet Metab 2019;126:S20. DOI
47. Alharbi FJ, Baig S, Auray-Blais C, et al. Globotriaosylsphingosine (Lyso-Gb3) as a biomarker for cardiac variant (N215S) Fabry
disease. J Inherit Metab Dis 2018;41:239-47. DOI
48. Lavalle L, Thomas AS, Beaton B, et al. Phenotype and biochemical heterogeneity in late onset Fabry disease defined by N215S
mutation. PLoS One 2018;13:e0193550. DOI PubMed PMC
49. Nowak A, Mechtler TP, Hornemann T, et al. Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients
with Fabry disease. Mol Genet Metab 2018;123:148-53. DOI
50. Liao HC, Huang YH, Chen YJ, et al. Plasma globotriaosylsphingosine (lysoGb3) could be a biomarker for Fabry disease with a
Chinese hotspot late-onset mutation (IVS4+919G>A). Clin Chim Acta 2013;426:114-20. DOI
51. Talbot A, Nicholls K, Fletcher JM, Fuller M. A simple method for quantification of plasma globotriaosylsphingosine: utility for
Fabry disease. Mol Genet Metab 2017;122:121-5. DOI
52. Sakuraba H, Togawa T, Tsukimura T, Kato H. Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme
replacement therapy. Clin Exp Nephrol 2018;22:843-9. DOI PubMed
53. Nowak A, Mechtler TP, Desnick RJ, Kasper DC. Plasma LysoGb3: a useful biomarker for the diagnosis and treatment of Fabry
disease heterozygotes. Mol Genet Metab 2017;120:57-61. DOI PubMed
54. Baydakova GV, Ilyushkina AA, Moiseev S, et al. α-Galactosidase A/lysoGb3 ratio as a potential marker for Fabry disease in females.
Clin Chim Acta 2020;501:27-32. DOI
55. Niemann M, Rolfs A, Störk S, et al. Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease. Circ
Cardiovasc Genet 2014;7:8-16. DOI
56. Ferreira S, Auray-Blais C, Boutin M, et al. Variations in the GLA gene correlate with globotriaosylceramide and
globotriaosylsphingosine analog levels in urine and plasma. Clin Chim Acta 2015;447:96-104. DOI PubMed PMC
57. Sueoka H, Ichihara J, Tsukimura T, Togawa T, Sakuraba H. Nano-LC-MS/MS for quantification of Lyso-Gb3 and its analogues
reveals a useful biomarker for Fabry disease. PLoS One 2015;10:e0127048. DOI PubMed PMC
58. Spada M, Kasper D, Pagliardini V, Biamino E, Giachero S, Porta F. Metabolic progression to clinical phenotype in classic Fabry
disease. Ital J Pediatr 2017;43:1. DOI PubMed PMC
59. Rombach SM, van den Bogaard B, de Groot E, et al. Vascular aspects of Fabry disease in relation to clinical manifestations and
elevations in plasma globotriaosylsphingosine. Hypertension 2012;60:998-1005. DOI
60. Biegstraaten M, Hollak CE, Bakkers M, Faber CG, Aerts JM, van Schaik IN. Small fiber neuropathy in Fabry disease. Mol Genet
Metab 2012;106:135-41. DOI PubMed
61. Rombach SM, Aerts JM, Poorthuis BJ, et al. Long-term effect of antibodies against infused alpha-galactosidase a in Fabry disease on
plasma and urinary (lyso)Gb3 reduction and treatment outcome. PLoS One 2012;7:e47805. DOI PubMed PMC
62. Effraimidis G, Feldt-Rasmussen U, Rasmussen ÅK, et al. Globotriaosylsphingosine (lyso-Gb3) and analogues in plasma and urine of
patients with Fabry disease and correlations with long-term treatment and genotypes in a nationwide female Danish cohort. J Med
Genet 2021;58:692-700. DOI
63. Hughes D, Gonzalez D, Maegawa G, et al. Long-term safety and efficacy of pegunigalsidase alfa: a multicenter 6-year study in adult
patients with Fabry disease. Genet Med 2023;25:100968. DOI
64. Mauhin W, Lidove O, Amelin D, et al. Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a
prospective analysis from the French multicenter cohort FFABRY. Orphanet J Rare Dis 2018;13:127. DOI PubMed PMC
65. Arends M, Wijburg FA, Wanner C, et al. Favourable effect of early versus late start of enzyme replacement therapy on plasma
globotriaosylsphingosine levels in men with classical Fabry disease. Mol Genet Metab 2017;121:157-61. DOI
66. Germain DP, Hughes DA, Nicholls K, et al. Treatment of Fabry’s disease with the pharmacologic chaperone migalastat. N Engl J
Med 2016;375:545-55. DOI
67. Müntze J, Gensler D, Maniuc O, et al. Oral chaperone therapy migalastat for treating Fabry disease: enzymatic response and serum
biomarker changes after 1 year. Clin Pharmacol Ther 2019;105:1224-33. DOI PubMed PMC
68. Hughes DA, Nicholls K, Shankar SP, et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy
in Fabry disease: 18-month results from the randomised phase III ATTRACT study. J Med Genet 2017;54:288-96. DOI PubMed
PMC
69. Riccio E, Zanfardino M, Ferreri L, et al. Switch from enzyme replacement therapy to oral chaperone migalastat for treating Fabry
disease: real-life data. Eur J Hum Genet 2020;28:1662-8. DOI PubMed PMC
70. Lenders M, Nordbeck P, Kurschat C, et al. Treatment of Fabry disease management with migalastat-outcome from a prospective 24
months observational multicenter study (FAMOUS). Eur Heart J Cardiovasc Pharmacother 2022;8:272-81. DOI PubMed
71. Nowak A, Huynh-Do U, Krayenbuehl PA, Beuschlein F, Schiffmann R, Barbey F. Fabry disease genotype, phenotype, and migalastat
amenability: insights from a national cohort. J Inherit Metab Dis 2020;43:326-33. DOI PubMed
72. Lenders M, Stappers F, Niemietz C, et al. Mutation-specific Fabry disease patient-derived cell model to evaluate the amenability to
chaperone therapy. J Med Genet 2019;56:548-56. DOI
73. Liu HC, Lin HY, Yang CF, et al. Globotriaosylsphingosine (lyso-Gb3) might not be a reliable marker for monitoring the long-term
therapeutic outcomes of enzyme replacement therapy for late-onset Fabry patients with the Chinese hotspot mutation (IVS4+